Clinical trials in Leidschendam – page 52

1 919 clinical trials in Leidschendam, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Leidschendam at a glance

1 919

clinical trials

Research sites1

Quick filters

1 919 trials in Leidschendam

Open in trial search

Pancreatic carcinoma+1

Recruiting

Study on FOLFIRINOX, Pembrolizumab, and SABR for Patients with Borderline Resectable Pancreatic Cancer

Registered drugNo placebo

Study on FOLFIRINOX, Pembrolizumab, and SABR for Patients with Borderline Resectable Pancreatic Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Neoplasm

Recruiting

Study of INBRX-109 with Irinotecan Hydrochloride Trihydrate and Temozolomide for Patients with Advanced Solid Tumors, Including Sarcomas

Registered drugNo placebo

Study of INBRX-109 with Irinotecan Hydrochloride Trihydrate and Temozolomide for Patients with Advanced Solid Tumors, Including Sarcomas

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Inhibrx Biosciences Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study of LB-100 and Atezolizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Study of LB-100 and Atezolizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Pfizer Inc.

Contact Research Centre

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Teriflunomide
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Asso De Recherche Cancers Gynecologiques

Contact Research Centre

Cardiogenic shock

Recruiting

Study on Esmolol Hydrochloride, Dobutamine, and Milrinone for Patients with Cardiogenic Shock on V-A ECMO Support

Registered drugNo placebo

Study on Esmolol Hydrochloride, Dobutamine, and Milrinone for Patients with Cardiogenic Shock on V-A ECMO Support

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dobutamine
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

Registered drugNo placebo

Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Hormone receptor positive breast cancer

Recruiting

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Neuromyelitis optica spectrum disorder

Recruiting

Study of Inebilizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

Study of Inebilizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Inebilizumab
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leidschendam

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatment advancements, evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

Advanced NSCLC treatments
Immunotherapy combinations
KRAS G12C inhibitors

Studies compare various treatment options to improve patient outcomes and survival rates.

02 Breast Cancer Studies

Comprehensive research into breast cancer treatments, particularly focusing on hormone receptor-positive and HER2-positive subtypes, investigating targeted therapies and chemotherapy combinations.

Metastatic breast cancer
HER2-positive therapy
Triple-negative breast cancer

Trials examine innovative treatment strategies and personalized approaches.

03 Hematologic Malignancies

Studies focusing on lymphoma treatments, including both Hodgkin and non-Hodgkin variants, evaluating response-adapted therapies and novel drug combinations.

Advanced Hodgkin Lymphoma
Follicular Lymphoma
Treatment optimization

Research aims to improve treatment outcomes while minimizing toxicity.

04 Gastrointestinal Oncology

Investigations into colorectal cancer and related conditions, including innovative surgical approaches and treatment strategies for recurrent disease.

Rectal cancer treatments
Esophagogastric cancer
Surgical innovations

Focus on improving surgical outcomes and treatment effectiveness.

05 Brain Metastases Research

Studies examining treatment options for cerebral radiation necrosis and brain metastases, including innovative detection methods and therapeutic approaches.

Radiation necrosis treatment
Metastatic detection
Targeted therapies

Research aims to improve detection and treatment of brain metastases.

Back to the Netherlands All countries